Regulatory Role of IL6 in Immune-Related Adverse Events during Checkpoint Inhibitor Treatment in Melanoma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910600 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Krishna P Singh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Biology & Bioinformatics, University of Rostock, 18051 Rostock, Germany. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Interleukin-6, Interleukin-6 Inhibitors. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Federal Ministry of Education and Research (BMBF).
Themen: Patientensicherheit
Abstract (Originalsprache)
The landscape of clinical management for metastatic melanoma (MM) and other solid tumors has been modernized by the advent of immune checkpoint inhibitors (ICI), including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors. While these agents demonstrate efficacy in suppressing tumor growth, they also lead to immune-related adverse events (irAEs), resulting in the exacerbation of autoimmune diseases such as rheumatoid arthritis (RA), ulcerative colitis (UC), and Crohn’s disease (CD). The immune checkpoint inhibitors offer promising advancements in the treatment of melanoma and other cancers, but they also present significant challenges related to irAEs and autoimmune diseases. Ongoing research is crucial to better understand these challenges and develop strategies for mitigating adverse effects while maximizing therapeutic benefits. In this manuscript, we addressed this challenge using network-based approaches by constructing and analyzing the molecular and signaling networks associated with tumor-immune crosstalk. Our analysis revealed that IL6 is the key regulator responsible for irAEs during ICI therapies. Furthermore, we conducted an integrative network and molecular-level analysis, including virtual screening, of drug libraries, such as the Collection of Open Natural Products (COCONUT) and the Zinc15 FDA-approved library, to identify potential IL6 inhibitors. Subsequently, the compound amprenavir was identified as the best molecule that may disrupt essential interactions between IL6 and IL6R, which are responsible for initiating the signaling cascades underlying irAEs in ICI therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Biology & Bioinformatics, University of Rostock, 18051 Rostock, Germany.
- Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow 226028, India.
- Department of Biomedical Engineering & Bioinformatics, Chhattisgarh Swami Vivekananda Technical University, Bhilai 491107, India.
- Leibniz Institute for Food Systems Biology, Technical University of Munich, 85354 Freising, Germany.
ORCID-Profile: Krishna P Singh, Anuj Singh, Olaf Wolkenhauer, Shailendra Kumar Gupta
Förderung
- German Federal Ministry of Education and Research (BMBF)
Zitieren
APA
Singh, K. P., Singh, A., Wolkenhauer, O., & Gupta, S. K. (2024). Regulatory Role of IL6 in Immune-Related Adverse Events during Checkpoint Inhibitor Treatment in Melanoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910600
Vancouver
Singh KP, Singh A, Wolkenhauer O, Gupta SK. Regulatory Role of IL6 in Immune-Related Adverse Events during Checkpoint Inhibitor Treatment in Melanoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910600
BibTeX
@article{Singh2024,
author = {Singh, Krishna P and Singh, Anuj and Wolkenhauer, Olaf and Gupta, Shailendra Kumar},
title = {Regulatory Role of IL6 in Immune-Related Adverse Events during Checkpoint Inhibitor Treatment in Melanoma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910600}
}
EUVIMED